Voya Investment Management LLC Has $447,000 Holdings in Agios Pharmaceuticals, Inc. $AGIO

Voya Investment Management LLC trimmed its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 53.8% during the first quarter, Holdings Channel.com reports. The institutional investor owned 15,247 shares of the biopharmaceutical company’s stock after selling 17,760 shares during the quarter. Voya Investment Management LLC’s holdings in Agios Pharmaceuticals were worth $447,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. PNC Financial Services Group Inc. boosted its holdings in shares of Agios Pharmaceuticals by 16.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 499 shares in the last quarter. CWM LLC boosted its holdings in shares of Agios Pharmaceuticals by 150.2% during the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 996 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the 1st quarter worth $40,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Agios Pharmaceuticals by 5.8% in the 1st quarter. Harbor Capital Advisors Inc. now owns 35,729 shares of the biopharmaceutical company’s stock worth $1,047,000 after purchasing an additional 1,962 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of Agios Pharmaceuticals by 28.8% in the 1st quarter. Victory Capital Management Inc. now owns 8,784 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 1,964 shares in the last quarter.

Agios Pharmaceuticals Stock Up 6.3%

AGIO stock opened at $38.93 on Friday. The firm has a market capitalization of $2.26 billion, a PE ratio of 3.54 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58. The stock has a 50-day simple moving average of $37.44 and a two-hundred day simple moving average of $33.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. On average, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Brian Goff sold 11,085 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $36.67, for a total transaction of $406,486.95. Following the transaction, the chief executive officer directly owned 123,528 shares of the company’s stock, valued at approximately $4,529,771.76. The trade was a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Theodore James Jr. Washburn sold 8,546 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $36.87, for a total value of $315,091.02. Following the transaction, the insider directly owned 868 shares in the company, valued at $32,003.16. This trade represents a 90.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 37,036 shares of company stock worth $1,369,980. Company insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $56.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 4th. Scotiabank cut their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a report on Monday, July 28th. Finally, Bank of America cut their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $56.00.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.